Search Within


Applied Filters:
Showing 1-4 of 4 results for "625-82-1" within Papers
A Fang et al.
HIV clinical trials, 13(1), 46-59 (2012-02-07)
Evaluate the safety, tolerability, and pharmacokinetics (PK) of nelfinavir during pregnancy and postpartum in HIV-infected women. Phase IV, non-randomized, open-label study of nelfinavir 625 mg tablets (1250 mg) in combination with lamivudine/zidovudine twice daily. Primary endpoint was treatment-related or possibly
I Feoktistov et al.
Biochemical pharmacology, 62(9), 1163-1173 (2001-11-14)
The antiasthmatic drug enprofylline was the first known selective, though not potent, A(2B) antagonist. On the basis of structure-activity relationships (SARs) of xanthine derivatives, we designed a novel selective adenosine A(2B) receptor antagonist, 3-isobutyl-8-pyrrolidinoxanthine (IPDX), with potency greater than that
Oliver Königsbrügge et al.
Annals of hematology, 94(9), 1463-1471 (2015-05-31)
Monitoring of anti-coagulation with the direct factor Xa inhibitor rivaroxaban is considered unnecessary in a routine clinical setting. However, assessment of its anti-coagulant effect may be desirable in certain clinical situations. We assessed prothrombin time (PT) reagents and commercially available
P C Chan
Toxicity report series, (67)(67), 1-G12-1-G12 (2004-05-18)
[Structure-see text] 2-Methylimidazole and 4-methylimidazole are intermediate/starting materials or components in the manufacture of pharmaceuticals, photographic and photothermographic chemicals, dyes and pigments, agricultural chemicals, and rubber; these chemicals have been identified as undesirable by-products in several foods and have been
Page 1 of 1